Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection

BACKGROUND: The use of sorafenib in the adjuvant management of hepatocellular carcinoma (HCC) is controversial. AIM: To analyze the effects of adjuvant sorafenib therapy in patients with HCC at high recurrence risk after radical resection. METHODS: This was a retrospective study of patients who unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qingli, Song, Tianqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495215/
https://www.ncbi.nlm.nih.gov/pubmed/34631511
http://dx.doi.org/10.3389/fonc.2021.633033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495215/
https://www.ncbi.nlm.nih.gov/pubmed/34631511
http://dx.doi.org/10.3389/fonc.2021.633033

Ejemplares similares